These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 18572757)

  • 1. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant.
    Sloan RD; Ijaz S; Moore PL; Harrison TJ; Teo CG; Tedder RS
    Antivir Ther; 2008; 13(3):439-47. PubMed ID: 18572757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B antiviral resistance and vaccine escape: two sides of the same coin.
    Torresi J
    Antivir Ther; 2008; 13(3):337-40. PubMed ID: 18572745
    [No Abstract]   [Full Text] [Related]  

  • 3. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
    Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
    J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
    Sayan M; Buğdacı MS
    Mikrobiyol Bul; 2013 Jul; 47(3):544-9. PubMed ID: 23971933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
    Choe WH; Hong SP; Kim BK; Ko SY; Jung YK; Kim JH; Yeon JE; Byun KS; Kim KH; Ji SI; Kim SO; Lee CH; Kwon SY
    Antivir Ther; 2009; 14(7):985-93. PubMed ID: 19918102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
    Gomes-Gouvêa MS; Ferreira AC; Teixeira R; Andrade JR; Ferreira AS; Barros LM; Rezende RE; Nastri AC; Leite AG; Piccoli LZ; Galvan J; Conde SR; Soares MC; Kliemann DA; Bertolini DA; Kunyoshi AS; Lyra AC; Oikawa MK; de Araújo LV; Carrilho FJ; Mendes-Corrêa MC; Pinho JR
    Antivir Ther; 2015; 20(4):387-95. PubMed ID: 25624410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
    Sayan M; Akhan SC
    Int J Infect Dis; 2011 Oct; 15(10):e722-6. PubMed ID: 21784687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
    Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
    Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hepatitis B infection associated with drug-resistant hepatitis B virus.
    Xu Z; Liu Y; Xu T; Chen L; Si L; Wang Y; Ren X; Zhong Y; Zhao J; Xu D
    J Clin Virol; 2010 Aug; 48(4):270-4. PubMed ID: 20580309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring "a" loop escape mutations.
    Cooreman MP; van Roosmalen MH; te Morsche R; Sünnen CM; de Ven EM; Jansen JB; Tytgat GN; de Wit PL; Paulij WP
    Hepatology; 1999 Nov; 30(5):1287-92. PubMed ID: 10534351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBV mutations associated with lamivudine therapy.
    Lapiński TW; Parfieniuk-Kowerda A; Trzos A; Jaroszewicz J; Kowalczuk O; Nikliński J; Flisiak R
    Przegl Epidemiol; 2013; 67(4):611-6, 705-8. PubMed ID: 24741905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.
    Torresi J; Earnest-Silveira L; Deliyannis G; Edgtton K; Zhuang H; Locarnini SA; Fyfe J; Sozzi T; Jackson DC
    Virology; 2002 Feb; 293(2):305-13. PubMed ID: 11886250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic backbone modulates the phenotype of hepatitis B surface antigen mutants.
    Beale MA; Ijaz S; Tedder RS
    J Gen Virol; 2010 Jan; 91(Pt 1):68-73. PubMed ID: 19759242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.